CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胰腺导管腺癌与免疫检查点抑制剂：免疫治疗的灰色帷幕与点点亮光
英文原题：Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
查看英文原题
Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胰腺导管腺癌（PDAC）是一种预后极差的疾病，5年总生存率约为10%。免疫疗法虽已革新临床肿瘤学，却未显著改善PDAC患者临床结局。尽管研究投入巨大，免疫检查点抑制剂（ICI）无论单药使用，还是联合化疗或靶向治疗，均未显示令人鼓舞的结果。这一失败反映出我们对免疫衰老关键因素及PDAC肿瘤微环境复杂性的认识不足。不过，PARP抑制剂联合治疗、疫苗和CAR-T 细胞疗法带来了一线希望。本文全面总结ICI用于PDAC的最新进展，重点介绍临床证据和在研研究，并分析免疫治疗失败的原因及可能解决方案。
展开英文摘要原文
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor 5-year overall survival rate (~10%). The revolution of immunotherapy in clinical oncology has not substantially changed clinical outcome for patients with PDAC. Despite outstanding efforts, neither immune checkpoint inhibitors (ICIs) alone, nor in combination with chemotherapy or targeted therapies have shown encouraging results. This failure mirrors the lack of knowledge about the real key players of immune system senescence and the complexity of the tumor microenvironment in PDAC.
However, some hope can be derived from PARP-inhibitor combinations, vaccines, and CAR-T-cells therapy. In this review, we comprehensively summarize the latest updates about the use of ICIs in PDAC, focusing on clinical evidence and ongoing studies highlighting explanations for the failure of immunotherapy and possible solutions.
论文信息
- 作者
- Balsano R、Zanuso V、Pirozzi A、Rimassa L、Bozzarelli S
- 单位
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.Italy
- 文献类型
- 综述
- 期刊
- Current oncology (Toronto, Ont.)2023 Mar 30
- 原文标识
- PubMed 37185406 · DOI 10.3390/curroncol30040293
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →